Literature DB >> 16023597

A mouse model for cyclin E-dependent genetic instability and tumorigenesis.

Keith R Loeb1, Heather Kostner, Eduardo Firpo, Thomas Norwood, Karen D Tsuchiya, Bruce E Clurman, James M Roberts.   

Abstract

Ubiquitination of murine cyclin E is triggered by phosphorylation on threonine 393. Cyclin E(T393A) knockin mice exhibited increased cyclin E stability, but no phenotypic abnormalities. Importantly, loss of the p53 pathway exacerbated the effect of the T393A mutation. Thus, in p21(-/-) cells the T393A mutation had an exaggerated effect on cyclin E abundance and its associated kinase activity, which caused abnormal cell cycle progression, and genetic instability involving chromosome breaks and translocations. Moreover, cyclin E(T393A) acted synergistically with p53 deficiency to accelerate tumorigenesis in cyclin E(T393A) p53(-/-) mice; Ras more readily transformed cyclin E(T393A) p53(-/-) cells than p53(-/-) cells in vitro; and cyclin E(T393A) mice had a greatly increased susceptibility to Ras-induced lung cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16023597     DOI: 10.1016/j.ccr.2005.06.010

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  63 in total

1.  DDX3 regulates cell growth through translational control of cyclin E1.

Authors:  Ming-Chih Lai; Wen-Cheng Chang; Sheau-Yann Shieh; Woan-Yuh Tarn
Journal:  Mol Cell Biol       Date:  2010-09-13       Impact factor: 4.272

Review 2.  Ubiquitin, the centrosome, and chromosome segregation.

Authors:  Ying Zhang; Paul J Galardy
Journal:  Chromosome Res       Date:  2016-01       Impact factor: 5.239

3.  NFAT1 transcription factor regulates cell cycle progression and cyclin E expression in B lymphocytes.

Authors:  Leonardo K Teixeira; Nina Carrossini; Cristiane Sécca; José E Kroll; Déborah C DaCunha; Douglas V Faget; Lilian D S Carvalho; Sandro J de Souza; João P B Viola
Journal:  Cell Cycle       Date:  2016-07-11       Impact factor: 4.534

Review 4.  Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials.

Authors:  Rosario Pivonello; Rosario Ferrigno; Maria Cristina De Martino; Chiara Simeoli; Nicola Di Paola; Claudia Pivonello; Livia Barba; Mariarosaria Negri; Cristina De Angelis; Annamaria Colao
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-08       Impact factor: 5.555

5.  Hyperplasia and spontaneous tumor development in the gynecologic system in mice lacking the BRCA1-Delta11 isoform.

Authors:  Sang Soo Kim; Liu Cao; Sung-Chul Lim; Cuiling Li; Rui-Hong Wang; Xiaoling Xu; Richard Bachelier; Chu-Xia Deng
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

6.  Constitutive turnover of cyclin E by Cul3 maintains quiescence.

Authors:  Justina D McEvoy; Uta Kossatz; Nisar Malek; Jeffrey D Singer
Journal:  Mol Cell Biol       Date:  2007-03-05       Impact factor: 4.272

7.  The cyclin E regulator cullin 3 prevents mouse hepatic progenitor cells from becoming tumor-initiating cells.

Authors:  Uta Kossatz; Kai Breuhahn; Benita Wolf; Matthias Hardtke-Wolenski; Ludwig Wilkens; Doris Steinemann; Stephan Singer; Felicitas Brass; Stefan Kubicka; Brigitte Schlegelberger; Peter Schirmacher; Michael P Manns; Jeffrey D Singer; Nisar P Malek
Journal:  J Clin Invest       Date:  2010-10-11       Impact factor: 14.808

Review 8.  In the wrong place at the wrong time: does cyclin mislocalization drive oncogenic transformation?

Authors:  Jonathan D Moore
Journal:  Nat Rev Cancer       Date:  2013-02-07       Impact factor: 60.716

9.  Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1.

Authors:  C Elizabeth Caldon; C Marcelo Sergio; Andrew Burgess; Andrew J Deans; Robert L Sutherland; Elizabeth A Musgrove
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

Review 10.  Role of prolonged mitotic checkpoint activation in the formation and treatment of cancer.

Authors:  W Brian Dalton; Vincent W Yang
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.